Showing results (131-140 of 151) with videos related to

Sort By:
Pageof 16
British Journal of Cancer|August 26, 2010
MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcomeJ C Hassel, A Sucker, L Edler, et al.
Investigational New Drugs|December 21, 2010
Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancerDirk Strumberg, Beate Schultheis, M E Scheulen, et al.
Pharmacogenetics|March 27, 2001
Relevance of N-acetyltransferase 1 and 2 (NAT1, NAT2) genetic polymorphisms in non-small cell lung cancer susceptibilityH Wikman, S Thiel, B Jäger, et al.
The Journal of Investigative Dermatology|September 1, 1991
Detection of Epstein-Barr virus-DNA in tongue epithelium of human immunodeficiency virus-infected patientsH Näher, L Gissmann, C von Knebel Doeberitz, et al.
Cancer Letters|December 13, 2005
Dexamethasone desensitizes hepatocellular and colorectal tumours toward cytotoxic therapyC Zhang, A Kolb, J Mattern, et al.
The European Respiratory Journal|August 1, 2009
Single nucleotide polymorphisms in matrix metalloproteinase genes and lung cancer chemotherapy response and prognosisD B Scherf, H Dally, P Müller, et al.
European Journal of Cancer (Oxford, England : 1990)|March 28, 2002
Gemcitabine, vinorelbine and cisplatin combination chemotherapy in advanced non-small cell lung cancer: a phase II trialE Laack, T Mende, H Dürk, et al.
British Journal of Cancer|November 28, 2007
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIVS Steinbild, K Mross, A Frost, et al.
Nucleic Acids Research|May 2, 2009
DIANA-microT web server: elucidating microRNA functions through target predictionM Maragkakis, M Reczko, V A Simossis, et al.
European Journal of Cancer (Oxford, England : 1990)|April 6, 2001
Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer: a phase II trialE Laack, T Mende, J Benk, et al.
Pageof 16